These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23408289)

  • 41. Pharmacological modulation of autophagy during cardiac stress.
    Sciarretta S; Zhai P; Volpe M; Sadoshima J
    J Cardiovasc Pharmacol; 2012 Sep; 60(3):235-41. PubMed ID: 22710813
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of redox signalling and autophagy during cardiovascular diseases-role of resveratrol.
    Fu DG
    Eur Rev Med Pharmacol Sci; 2015 Apr; 19(8):1530-6. PubMed ID: 25967730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics.
    Rubattu S; Volpe M
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular effects of phosphodiesterase 5 inhibitors.
    Reffelmann T; Kloner RA
    Curr Pharm Des; 2006; 12(27):3485-94. PubMed ID: 17017941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abstracts of the 13th International Congress on Cardiovascular Pharmacotherapy. November 29-December 2, 2007. Antalya, Turkey.
    Remme WJ
    Cardiovasc Drugs Ther; 2007 Nov; 21 Suppl 1(1):S6-43. PubMed ID: 17963033
    [No Abstract]   [Full Text] [Related]  

  • 46. Opioids in Cardiovascular Disease: Therapeutic Options.
    Rawal H; Patel BM
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):279-291. PubMed ID: 29528698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.
    Masoudkabir F; Sarrafzadegan N; Gotay C; Ignaszewski A; Krahn AD; Davis MK; Franco C; Mani A
    Atherosclerosis; 2017 Aug; 263():343-351. PubMed ID: 28624099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SIRT1 in cardiovascular aging.
    Luo XY; Qu SL; Tang ZH; Zhang Y; Liu MH; Peng J; Tang H; Yu KL; Zhang C; Ren Z; Jiang ZS
    Clin Chim Acta; 2014 Nov; 437():106-14. PubMed ID: 25063737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intracellular toxic advanced glycation end-products in cardiomyocytes may cause cardiovascular disease.
    Takata T; Sakasai-Sakai A; Ueda T; Takeuchi M
    Sci Rep; 2019 Feb; 9(1):2121. PubMed ID: 30765817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exercise-mediated regulation of autophagy in the cardiovascular system.
    Wang L; Wang J; Cretoiu D; Li G; Xiao J
    J Sport Health Sci; 2020 May; 9(3):203-210. PubMed ID: 32444145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abstracts of the 11th International Congress on Cardiovascular Pharmacotherapy. Montreal, Canada, 18-21 May 2002.
    Cardiovasc Drugs Ther; 2002; 16 Suppl 1():5-116. PubMed ID: 12108434
    [No Abstract]   [Full Text] [Related]  

  • 52. The importance of drug discovery for treatment of cardiovascular diseases.
    Kennedy C
    Future Med Chem; 2013 Mar; 5(4):355-7. PubMed ID: 23495678
    [No Abstract]   [Full Text] [Related]  

  • 53. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Action mechanism and cardiovascular effect of anthocyanins: a systematic review of animal and human studies.
    Reis JF; Monteiro VV; de Souza Gomes R; do Carmo MM; da Costa GV; Ribera PC; Monteiro MC
    J Transl Med; 2016 Nov; 14(1):315. PubMed ID: 27846846
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
    Ghigo A; Morello F; Perino A; Hirsch E
    Future Med Chem; 2013 Mar; 5(4):479-92. PubMed ID: 23495693
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The interplay between autophagy and mitochondrial dysfunction in oxidative stress-induced cardiac aging and pathology.
    Wohlgemuth SE; Calvani R; Marzetti E
    J Mol Cell Cardiol; 2014 Jun; 71():62-70. PubMed ID: 24650874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023.
    Tamargo J; Agewall S; Borghi C; Ceconi C; Cerbai E; Dan GA; Ferdinandy P; Grove EL; Rocca B; Magavern E; Sulzgruber P; Semb AG; Sossalla S; Niessner A; Kaski JC; Dobrev D
    Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):219-244. PubMed ID: 38379024
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting autophagy as a strategy for drug discovery and therapeutic modulation.
    Gao L; Jauregui CE; Teng Y
    Future Med Chem; 2017 Mar; 9(3):335-345. PubMed ID: 28176543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Natural products as modulator of autophagy with potential clinical prospects.
    Wang P; Zhu L; Sun D; Gan F; Gao S; Yin Y; Chen L
    Apoptosis; 2017 Mar; 22(3):325-356. PubMed ID: 27988811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of cell death in the cardiovascular system.
    Patel P; Karch J
    Int Rev Cell Mol Biol; 2020; 353():153-209. PubMed ID: 32381175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.